Thursday 16 October, 2025
Introduction/Objectives: Type 2 diabetes mellitus (T2DM) is a complex multifactorial disorder, impacted by several genetic and environmental factors. Overweight and obesity…
Read morePoster: Drug/Disease Modelling - Endocrine
Population PK/PD analysis of ropinirole as a potential treatment for hyperprolactinemia
Thursday 16 October, 2025
Objectives: While ergoline dopamine agonists are standard therapies for the treatment of hyperprolactinemia and prolactinomas, in a subset of patients their…
Read morePK and PD modeling and simulation of GX-H9 in the adult patients with growth hormone deficiency
Thursday 16 October, 2025
Objectives: Adult growth hormone deficiency (AGHD) is known as clinical syndrome associated with a number of metabolic abnormalities, including abnormal body…
Read moreUnderstanding the relationship between in vitro potency, nausea and clinical efficacious concentrations for GLP-1 receptor agonists
Thursday 16 October, 2025
Objectives: GLP-1 receptor agonists (GLP-1RAs) represent a compound class that play an important role in type 2 diabetes treatment. As…
Read moreModel based Phase 2 Dose Selection of BIIB059 in Subjects with Systemic and Cutaneous Lupus Erythematosus (SLE and CLE)
Thursday 16 October, 2025
Objectives: BIIB059 (anti-BDCA2) is a humanized, immunoglobulin G1 (IgG1) monoclonal antibody currently under development for treatment of SLE including CLE….
Read moreA Model-Based Meta-Analysis (MBMA) of Efficacy of Different Drugs for Postmenopausal Vasomotor-Symptoms
Thursday 16 October, 2025
Objectives: Model-based meta-analysis (MBMA) allows to compare the clinical outcomes with different drugs that have not been compared directly using…
Read moreA population pharmacokinetic/pharmacodynamic analysis of rosuvastatin according to OATP1B1 and BCRP polymorphisms in young and elderly subjects
Thursday 16 October, 2025
Introduction: Rosuvastatin is one of the most hydrophilic statins (3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase inhibitors) used for the treatment of hyperlipidemia. Rosuvastatin…
Read moreA Comprehensive Model-Based Meta-Analysis (MBMA) of Diabetes Studies in Type 2 Diabetes Mellitus Patients to Quantify the Relationship between HbA1c and Fasting Plasma Glucose
Thursday 16 October, 2025
Objectives: Describe the relationship between fasting plasma glucose (FPG) and HbA1c to predict long term efficacy from early clinical outcome…
Read moreDevelopment of a Quantitative Systems Pharmacology Model to Support Dosing of rhPTH(1-84), a Recombinant Human Parathyroid Hormone, in Adult Patients with Hypoparathyroidism
Thursday 16 October, 2025
Objectives: rhPTH(1-84), a full-length Recombinant Human Parathyroid Hormone, is approved in the US and Europe as an adjunct to calcium…
Read moreEvaluation of immediate release exenatide effects on gastric motility and intestinal glucose absorption using a systems pharmacology model
Thursday 16 October, 2025
Objectives: Glucagon-like peptide (GLP)-1 and other GLP-1 receptor agonists such as exenatide have been shown to decrease gastric motility [1,2]….
Read more